Bryan Johnson

Bryan Johnson is an American entrepreneur who moved from payments and deep-tech investing into a public, data-driven longevity experiment. His earlier identity is anchored in Braintree/Venmo, OS Fund, and Kernel: OS Fund says he invested $100M into OS Fund in 2014, founded Kernel in 2016 with another $100M commitment, and previously founded Braintree, sold to PayPal in 2013 for $800M. The University of Chicago profile frames this as a post-Braintree pivot from commerce infrastructure toward “help humanity thrive” ventures in engineered biology, climate/health deep tech, and brain interfaces.

Since 2021, Johnson’s public center of gravity has been project blueprint, a self-experiment intended to measure 70+ organs, quantify biological age, and use an evidence-and-biomarker feedback loop to choose interventions. In the original Project Blueprint post, Johnson described “firing Evening Bryan” from food decisions, shifting decision authority from preference to biomarkers, and treating Blueprint as a “stock ticker” for the current state of anti-aging science, albeit explicitly as an N=1 experiment.

Johnson’s worldview now fuses personal health optimization with the broader dont die frame: death, biological aging, planetary risk, and AI-era existential risk are treated as problems for coordinated measurement, technology, community, and norm formation. His home page presents three pillars: Don’t Die as community, Protocol as freely available information, and Blueprint as interventions/commerce.

In a July 28 autobiographical essay, Johnson supplied a more detailed origin story for that system. He said flight training taught him to see safety and performance as products of checklists, protocols, and active risk management; he then applied that model to evening overeating by having his morning self pre-commit to a 5 p.m. food cutoff. Johnson says the combination of aviation culture, Kernel, AI, and automation later became his idea of an “Autonomous Self” and the first human prototype for Don’t Die. This is his personal retrospective, not evidence that the routine treats depression, that the cutoff is generally appropriate, or that his reported results generalize.

Key entities and relationships

• project blueprint — Johnson’s protocol, self-experiment, product ecosystem, and measurement methodology.
• dont die — the community/ideology that generalizes his health project into a civilizational slogan.
• Kernel — neurotechnology company founded by Johnson; relevant to his recurring “what we measure, we improve” thesis.
• OS Fund — deep-tech fund founded/co-founded by Johnson; part of his post-Braintree capital allocation thesis.
• Braintree/Venmo — the payments company/acquisition that funded later projects.

Recurring claims in Johnson’s own materials

Johnson claims to be among the most biologically measured people, and his protocol page lists percentile-style outcomes across muscle, fat, bone mineral density, resting heart rate, fertility, blood pressure, vascular function, sleep, grip strength, glucose, and blood-sugar control. These are primary-source self-reports and should be treated as claims requiring context rather than independent clinical validation.

On X/Twitter in May 2026, Johnson’s messaging emphasized sleep, resting heart rate before bed, biomarkers-in-context, sauna experiments, peptide experiments, certified products, and scaling a “female Bryan Johnson” / female-specific protocol via Kate Tolo. This shows that the public project is no longer just a static protocol; it is a daily media feed of experiments, product launches, health claims, and “Don’t Die” norm-setting.

On May 23–24, 2026, Johnson also used X/Twitter to frame his Enhanced Games commentary role as “Human Enhancement Expert”: he highlighted athlete measurement, claimed medical supervision and optional enhancement, and tied performance-enhancing protocols to the same measurement-first posture that runs through biomarker driven longevity protocols. The posts are useful evidence for his public positioning, but not independent validation of Enhanced Games safety or efficacy.

In June 2026, Johnson’s feed added two durable dashboard themes. First, he announced a prescription-therapeutics layer at medicine.immortals.com, describing Tadalafil/Cialis, Metformin, Oral Minoxidil, Tretinoin, Estradiol, and Acarbose as prescriptions he personally uses via licensed doctors and pharmacies. Second, he highlighted daily 5 mg Tadalafil/Cialis as a blood-flow/longevity intervention while explicitly caveating that the cited outcome data are observational associations, not proof of causation or medical advice. Treat both as Johnson/Blueprint commercial and protocol claims, not clinical recommendations.

The same June batch continued everyday protocol storytelling: quantified jet-lag recovery claims, sleep-as-recovery messaging, and a vegetable/legume-heavy breakfast example. Those posts are useful for showing how Blueprint blends measurement, routine snapshots, and product expansion, but they should stay in the claim/context lane rather than being rendered as personal health instructions.

On June 16–17, Johnson added a tighter methodological arc: a sauna/HSP27 self-experiment using ingestible core-temperature tracking, repeated blood draws, and a later heart-rate trace; then a Nature-feature thread with a formal Blueprint/Immortals essay arguing that RCTs are necessary but not sufficient for individualized longevity optimization. The public-site stance is to surface the measurement method and mainstream-attention signal while preserving Johnson’s own caveat that the listed first-in-human biological observations need further validation.

On June 21, Johnson’s feed turned from biomarker claims to media and fatherhood positioning. A reply to Ezra Klein and Gary Shteyngart pushed back on being framed as “modern dystopia” and re-articulated Don’t Die as a rejection of YOLO-style acceptance of self-destructive habits. Two other posts described parenting mental models and a childhood exercise in giving away water and bars without reward, using overjustification effect and moral elevation language. These are public-persona and ideology signals, not health-protocol evidence.

On June 22, the feed returned to commercial health infrastructure: Johnson announced that Immortals Rx had expanded into “microdose” GLP-1s, peptides, and NAD+, listing semaglutide/Wegovy, tirzepatide/Zepbound, SGLT2 inhibitors, peptide complexes, glutathione, and NAD+ alongside the earlier tadalafil/metformin/minoxidil/tretinoin/acarbose stack. The same batch included a fermented-foods post citing an unnamed randomized trial, a biological-age joke, and an N=1 meibomian-gland dry-eye procedure report. The Rx expansion is dashboard-level business/protocol news; the food and procedure posts remain attributed claims or self-reports, not medical advice.

On June 23, Johnson used a long endorsement of the third-party “Midjourney scanner” to state a clearer measurement model: blood draws for chemical state, wearables for function, and imaging for structural state, with baseline + longitudinal tracking as the real unlock. The same batch added a public exchange with Nassim Nicholas Taleb about attribution/confounding, a personal “one international trip per quarter” travel cap derived from China/India/Australia biomarker recovery, and a detailed preview of Kate Tolo’s cycle-anchored daily measurement routine for the female protocol. These are useful signals about Johnson’s measurement worldview and public reception, but the scanner, travel rule, and female-protocol readouts remain attributed claims or exploratory protocol design rather than clinical advice.

On June 24, Johnson published two durable posts. The first was his clearest structured immortality manifesto, defining immortality as life expectancy outpacing aging and arguing from biology, AI capability, and Johnson-reported AI-assisted cancer anecdotes before introducing the “Die Economy” versus “Don’t Die Economy” frame for Immortals. The second defended consumer wearables as relative-tracking tools despite divergent absolute readings across brands. Together they sharpen the split between Johnson’s low-confidence future ideology and his medium-confidence measurement methodology; neither should be read as personal medical advice or independent validation of the claims.

On June 25, Johnson’s most substantive new post was a self-reported inherited-cancer screen: a combined DNA + RNA panel across 71 genes, with a negative result. He framed it as early risk stratification for surveillance rather than a cancer diagnosis. The same batch repeated his sleep-as-longevity-drug checklist and amplified New York Post coverage of Kate Tolo’s skin-age biohacking; those are recurring sleep/female-protocol signals, while the cancer panel is the novel measurement addition.

On June 26, Johnson followed that cancer-risk theme with a single biological-age post. He cited an unnamed study claiming that people whose biological age runs ahead of chronological age have higher early-cancer risk under 55, with the widest gaps associated with higher lung, uterine, and gastrointestinal cancer risk. The post is useful as a bridge between his biological-age-clock messaging and cancer-surveillance frame, but remains a tweet-level lay citation rather than independently verified medical guidance.

On June 27, Johnson’s feed shifted from biomarker claims to cultural reception. He quote-tweeted a TBPN video claiming French cigarette packs had reappropriated his image and Don’t Die slogan, then joked about being “the face of French cigarettes” while nudging smokers toward sleep. Because the underlying claim is third-party and unverified, the dashboard records it only as a meme/brand-reception signal. A second post that day urged care for self, others, the planet, animals, and life; it restates the Don’t Die worldview without adding a new protocol or medical claim.

On June 28, Johnson used a Charlie Munger psychology-of-misjudgment thread to explain why “smart people” neglect health: delayed incentives, slow decline, consistency pressure, denial, and avoiding tests to avoid bad news. This is useful public-persona context because it shows Johnson translating Don’t Die into behavioral economics language, but it remains attributed framing rather than clinical evidence or a new protocol.

On June 29–30, Johnson moved briefly outside the health stack into AI-governance speculation. One high-reply post asked, “Who would you trust to run the world?” and a longer essay argued that “rights follow from relative competence,” so adult rights could be curtailed if AI proves better at driving, law, medicine, finance, governance, and similar domains. He explicitly hedged that he was not advocating the future or calling it inevitable. The dashboard treats this as a low-confidence opinion signal about Johnson’s broader future-of-humanity reasoning, not as a Blueprint, biomarker, or medical claim.

Later on June 30, Johnson returned to health with one of his most substantive personal disclosures: he said he had been formally diagnosed with autoimmune gastritis after years of low ferritin that did not progress to anemia and therefore was easy for prior care teams to dismiss. His account says the diagnosis came through anti-parietal-cell antibody bloodwork, a bi-directional endoscopy, and five stomach biopsies, after an overhauled medical team revisited the unresolved iron-storage signal. The same post named Immortals Care as a “$1M a year protocol” and sketched a four-tier autoimmune-gastritis roadmap, from current support/monitoring to explicitly investigational JAK/STAT, IL-17, regulatory-T-cell, CAAR-T, and AI-designed-antibody ideas. Treat this as Johnson’s self-reported diagnosis and research agenda; the advanced tiers are not approved cures or reader advice. The same daily batch also included a longevity ↔ AI-compute investment disclosure in Etched, which he framed as infrastructure for drug-discovery search, and a Kate Tolo / WSJ media-reach update for the female-health protocol.

On July 3, Johnson continued the AIG story with a diagnostic follow-through thread: he said he is sequencing 1,000,000 individual immune cells to identify the autoreactive “rogue” clones attacking his stomach lining. Replies quantified the draw as 198.5 mL, 33 tubes, 50 tests, roughly 100 biomarkers, and the 1M-cell decode, and reported he was “no longer iron deficient” after a 1,000 mg Monoferric infusion. A longer follow-up pushed back on meat/sunlight/food “cure” suggestions, arguing low ferritin is downstream of parietal-cell destruction and that targeted therapy requires identifying the immune-cell clone/receptor pattern first. Treat the sequencing as Johnson’s self-reported measurement modality and diagnostic reasoning, not an established AIG cure or reader testing advice.

On July 8, Johnson published his most explicit AIG cure attempt: a five-step plan that uses the prior diagnosis and 1M-cell immune map, adds a second stomach biopsy to collect live T-cells, watches for flare-ups through biweekly blood draws plus wearable data, cryopreserves immune cells for a “Bryan in a dish” testing model, and then evaluates precision therapies through computer modeling and ex-vivo cell testing before any in-body attempt. This is important public-positioning evidence because it turns the AIG story into a personal immune-engineering roadmap. It is still a prospective experiment, not proof of a cure or medical advice.

On July 9, Johnson announced that Kate Tolo had been diagnosed with endometriosis without surgery after a three-modality workup: endo-specific ultrasound, AI-assisted pelvic MRI, and a microRNA/protein blood test, after standard imaging had reportedly missed the condition. The post continues the female-protocol thread from May and gives Johnson a second public disease case, alongside his AIG story, for arguing that persistent symptoms and false negatives should trigger deeper measurement. His “Phase II is curing endometriosis” language is recorded as movement/research positioning, not evidence of an available cure or reader medical advice.

On July 10–11, Johnson’s feed returned to foundations and self-reported outcomes rather than introducing a new protocol. He called “removing harm” his best-performing longevity therapy, listing sleep deprivation, inconsistent sleep, sedentary behavior, alcohol, nicotine, late-night eating, loneliness, poor air and water, and other exposures. He also reported 99.6th-percentile bone mineral density, 11.3% body fat, and 160.1 lb lean mass, then cited unnamed cohort summaries connecting body composition with mortality. The subtraction post is useful as behavior philosophy; the body-composition values and epidemiological effect sizes remain Johnson’s self-report and lay citations, not independent validation or reader targets.

On July 14, Johnson added two durable measurement-and-behavior frames. He announced a 90-day Kate Tolo program projected to span three menstrual cycles, 50+ devices, 100 daily tasks, 1,900 biomarkers, and 14.8M data points, presenting the effort as making female health “legible.” He also named resting heart rate his “Sovereignty Index,” reported a personal 41 bpm 30-day average, and paired it with evening pre-commitments around food, screens, caffeine, light, and bedtime. The former is a planned N=1 program, not completed female-health evidence; the latter is a behavioral metaphor and self-reported metric, not a universal target or medical advice. A same-day cooperative-AGI reflection was captured in the wiki but not promoted as a standalone public signal because it did not materially change the health, protocol, or Don’t Die model.

On July 16, Johnson amplified an unnamed laboratory result about enzymatically reversing age-related sugar–protein crosslinks. His post says researchers used AlphaFold to search 45,000 oxidases and directed evolution to screen more than 500 million engineered variants. The work remains ex vivo, however, and Johnson explicitly identified safe delivery of a large bacterial enzyme into living tissue—with adequate penetration and bioavailability—as an unresolved challenge. The dashboard records this as a low-confidence research-watch signal, not a demonstrated human treatment, protocol change, independent scientific validation, or medical advice.

On July 20, Johnson said an unspecified “incurable disease” diagnosis had shifted his project “overnight” from longevity staples toward disease resolution and frontier biotech. A same-day thread asked whether eye health is missing from longevity discussions and clarified that his interest is in robust measurement, dysfunction diagnosis, and corrective protocols rather than only diet or supplements. This is a material strategy and measurement-agenda signal, but the posts do not name the disease, connect it explicitly to his previously disclosed autoimmune gastritis, or provide research targets, tests, therapies, or outcomes. The dashboard therefore keeps the update in the attributed-positioning lane rather than treating it as evidence of a treatment or as medical advice.

On July 21, Johnson supplied two concrete follow-ups. First, he described a dish-grown, autologous reprogrammed-cell model as a newborn “clone” of himself and proposed therapy testing, organ growth, cell transplantation, and disease repair, attributing the process to Yamanaka factors and induced pluripotency. The source does not establish that a human clone exists or provide cell-line characterization, cited trials, safety data, an organ, a treatment, or an outcome, so the dashboard records speculative frontier-biotech and immortality positioning. Second, he reported collecting tears for a $1,800 specialty-lab panel across 15 ocular biomarkers, with a future eye protocol promised but no result, diagnosis, intervention, clinical-utility evidence, or outcome published. A high-engagement kindness/cortisol post from the same batch remains unpromoted because its health claims were unsourced and did not change the protocol model.

On July 22, Johnson returned to the commercial prescription layer, saying Immortals Rx now lists six GLP-1 options: Zepbound, Wegovy injections/tablets, Foundayo tablets, compounded tirzepatide, and compounded semaglutide. He framed the catalog around weight loss, food-noise management, and possible longevity relevance after a time-zone shift. The same batch included a detailed personal routine snapshot with IHHT, repeated biological sampling, exercise, and a 200°F dry sauna. The dashboard promotes the catalog as product news and keeps the routine as context; neither is evidence of longevity efficacy, a treatment recommendation, or independent verification of the named formulations and availability.

On July 23, Johnson translated his earlier sauna/HSP27 self-experiment into a broad public checklist. He recommended 4–7 dry-sauna sessions weekly, offered example time/temperature and core-temperature targets, and added advice or claims about acclimation, post-workout timing, hydration, fertility, cold plunging, recovery, microplastics, air quality, materials, and clothing. A separate post reported that moving his final meal from noon to 2 p.m. raised his sleep heart rate from 42 to 44 bpm and used engineering analogies to defend treating small changes as measurable inputs. The dashboard records both as attributed N=1 protocol positioning; they are not validated causal estimates, universal targets, personal medical advice, or independent evidence of longevity benefit.

On July 24, Johnson made the disease-resolution pivot more concrete at the company level. He said Immortals would keep its nutrition, GLP-1, longevity-medicine, hormone, peptide, biomarker, and concierge-medicine work while adding induced pluripotent stem cells, organoids, deep cellular characterization, and personalized therapy development as infrastructure for individuals to discover and resolve their own health issues. This is a material strategy and product-direction signal, but not evidence that the proposed platform can diagnose or cure disease, that the named technologies are clinically available through Immortals, or that any treatment is safe or effective.

On July 25, Johnson published an operational snapshot of Kate Tolo’s female-health program: a 100-day baseline before interventions, 14 million claimed menstrual-cycle data points, 100+ daily tasks, 50+ devices, and a 12-person medical team. The schedule spans repeated samples, hormonal and metabolic measures, wearables, functional and sensory testing, imaging, microbiome work, exercise, sleep, mood, and routine care. The dashboard treats this as one intensively measured N=1 program—not a completed dataset, representative female-health study, general protocol, or medical advice. A same-day dunk-training post was retained in the private source corpus but not promoted because it did not materially change the public knowledge model.

On July 30–31, the feed added two useful N=1 examples. Johnson said one week of eating animal protein after six years of a plant-forward diet coincided with a 61% drop in two named fiber-associated bacteria and a 2.5× increase in bile-tolerant bacteria; he explicitly limited the claim to his own measured response rather than arguing against meat. Johnson and Kate Tolo also said they froze roughly 10 mL of menstrual blood and proposed it as a repeatable, non-invasive uterine sample. No assay method or result was published for the menstrual-blood proposal, so the dashboard promotes the new measurement category while treating both items as attributed self-experiments—not dietary guidance, a validated diagnostic test, a biopsy substitute, or medical advice.

On August 3, Johnson quote-posted a cancer-research summary claiming that Viagra plus statins may blunt cancer spread. He cited 18% lower colorectal-cancer mortality and 15% lower metastasis, described a cholesterol-related mechanism, and proposed that the mechanism could apply to tadalafil. Johnson also stated that the underlying study was preclinical and that human evidence was observational. The dashboard therefore records a low-confidence, product-adjacent research claim—not evidence that sildenafil, tadalafil, or statins prevent metastasis, a reason to combine medicines, or medical advice. A separate report of feeling better after a 48-hour social-media fast was skipped as a subjective, low-signal self-report.

On August 4, Johnson said his longevity infrastructure took five years to build, while his team assembled Kate Tolo’s female-health protocol in 90 days and made it “better.” The comparison is useful as a strategy signal: he is presenting the measurement system as something a team can reproduce and improve rather than only as his personal routine. Because the post defines no quality criteria and publishes no comparative measurements or outcomes, the dashboard does not treat it as evidence of clinical superiority or generalizability. His same-day AI reflection and bowel-movement reaction were left out as philosophical or low-signal chronology.

On August 12–13, Johnson published two measurement-scale updates. He reported a 47-tube, 250 mL blood draw for single-cell sequencing of circulating immune cells plus inflammation, oxidative-stress, vascular, metabolic/lipid, glucose-regulation, and brain-related measures. The next day he promoted a Baseten event offering biological-age evaluations across brain, skin, strength, balance, reaction speed, and mobility. These posts show the project widening both its molecular and functional measurement surfaces, but they publish no results, test-performance evidence, clinical interpretation, or proof that the measurements improve outcomes.

In a separate August 13 post, Johnson summarized an unnamed mouse study in which aging reportedly narrowed microscopic fluid-drainage openings behind the nose and reduced total outflow by 40–50%, while one intranasal gene therapy enlarged downstream drainage structures and restored flow to young-adult levels within six weeks. The dashboard records this as low-confidence preclinical research watch: the post supplied no paper, human evidence, translational safety data, or connection to a Blueprint intervention. The same batch’s uncited sleep/attractiveness claim, and the prior day’s uncited cooking/AGEs recommendation, were not promoted as reader guidance.

On August 16, Johnson responded to people characterizing his dietary control as an eating disorder. He described years of discipline as mastery, said he is accountable to biomarkers and changes the protocol according to data, and acknowledged that the pursuit can move into unhealthy territory. The dashboard records this as a current algorithmic-health and behavior-design position. It is Johnson’s personal self-description—not a clinical diagnosis, proof that his eating pattern is safe or appropriate for others, or medical advice.

On August 18–19, Johnson published three higher-signal updates. He disclosed advanced meibomian-gland dysfunction diagnosed after a stye visit—meibography imaging plus Schirmer testing showing gland dropout and aqueous deficiency—and a four-therapy eye stack (IPL, radiofrequency, intraductal probing, 630nm red light) with a self-reported 30% gland-function improvement, while naming drivers inside his own protocol such as a topical anti-androgen and low insulin/IGF-1 signaling. He also highlighted a tumor-fingerprint mRNA immunotherapy paired with Keytruda that he says has reached a Phase 3 trial, and quote-posted the finale of Ross Douthat’s New York Times podcast featuring him, saying Don’t Die is “being metabolized by society.” The dashboard records the eye post as an attributed N=1 diagnosis-and-intervention account, the mRNA post as low-confidence third-party research commentary naming no trial or paper, and the podcast post as media reception. None are reader guidance or medical advice; lower-signal same-period posts (a focus-frustration reflection and dunk-training updates) were reviewed but not promoted.

On August 20, Johnson announced he adopted a Belgian Malinois named Katara and paired the announcement with the claim that dog owners have about a 24% lower risk of dying early—his highest-engagement post of the August 18–20 window. The figure traces to real literature: an unadjusted 2019 meta-analysis of 10 observational studies covering ~3.8 million participants (Kramer et al., Circulation: Cardiovascular Quality and Outcomes) reported exactly that association, while a 2020 reappraisal re-pooling the same studies with confounder-adjusted estimates found the all-cause mortality association statistically nonsignificant (pooled RR ≈ 0.93), with residual protective signal mainly in people with existing cardiovascular disease. The dashboard records this as an attributed observational claim with contested adjustment—not a demonstrated causal effect, a health recommendation to adopt a dog, or medical advice. A same-day sun/oxygen aphorism and the dog’s-name follow-up were reviewed but not promoted separately.

On August 22, his 49th birthday, Johnson posted a short anti-death allegory calling death the “biggest villain”—romanticized, defended, and worshiped—after listing the enemies people usually focus on (political parties, religions, nations, competitors, ideologies, individuals). The dashboard records this as a rhetorical restatement of the Don’t Die worldview, not evidence about mortality or any intervention. His same-day birthday video and a joking “predict my death” post (with his zodiac-year correction from horse to snake) were reviewed and kept as chronology only.

On August 24, Johnson quote-posted Kate Tolo’s thread on cycle-phase cholesterol variation with “check your girl’s blood work…,” amplifying the claim that women in their 30s labeled with high cholesterol may be misdiagnosed because cholesterol swings ~19% across the menstrual cycle—higher in the follicular half, lowest just before the period. Tolo cited the FDA’s 1977 exclusion of women from early drug trials and announced her own $2.6M, 14-million-datapoint cycle experiment. The claims track the NIH BioCycle study (Mumford et al., 2010: ~19% mean within-woman total-cholesterol variation; 14.3% vs 7.9% above the 200 mg/dL boundary in follicular vs late-luteal testing) and a 2011 review recommending cycle-aware timing, but the thread names no study and its “~6% mislabeled” figure does not precisely match published results (5% high at all visits; 19.7% at least once). The dashboard records attributed claims with literature context—not a directive to reinterpret labs without a clinician, and not medical advice. The same batch’s Baseten event promotion, hardware/health question, testosterone-culture post, birthday-note post, and food-mastery aphorism were reviewed and kept as chronology or low-signal positioning.

On August 25, Johnson posted an exercise prescription—3 workouts a week for 8 weeks, each built from four 4-minute intervals at 90–95% effort separated by 3 easy minutes—claiming a “lower risk of dying from any cause by 11% in 8 weeks” and closing that “your improved cardiorespiratory fitness is the risk reduction.” The protocol is the Norwegian 4×4 from Helgerud et al., 2007 (Med Sci Sports Exerc; 40 moderately trained men, workload-matched, 3 sessions/week for 8 weeks: +7.2% VO2max versus no change for moderate continuous training), and the mortality arithmetic tracks the Kodama et al., 2009 JAMA meta-analysis (33 studies, 102,980 participants: 13% lower all-cause mortality per additional MET of fitness, RR 0.87, 95% CI 0.84–0.90). No trial has measured mortality outcomes from eight weeks of intervals; the 11% compresses an RCT fitness outcome and a long-run observational association into an unattributed figure, and the post names no study. The dashboard records an attributed exercise claim with literature context—not a demonstrated 8-week mortality outcome, an exercise prescription, or medical advice. A same-day post noting that roughly two-thirds of humanity believes in some form of life after death was reviewed and kept as chronology-only philosophy commentary.

On August 26, Johnson turned to LDL cholesterol, calling it “one of the most actionable things from a blood draw” and citing “a meta analysis of 49 randomized trials and 312,175 people” for ~23% fewer major vascular events per 39 mg/dL (1 mmol/L) LDL reduction. He added that nutrition can do some of the heavy lifting—“dropping LDL levels by 13-14% over six months by combining viscous fiber, nuts, plant protein, and plant sterols”—and that “medications can also serve a role.” The figures are faithful to their sources once named: the meta-analysis matches Sabatine et al., 2016 (JAMA; 49 trials, 312,175 participants, 39,645 major vascular events: RR 0.77 per 1 mmol/L reduction, 95% CI 0.75–0.79, pooled across statin and LDL-receptor-upregulating nonstatin therapies), and the diet figure matches the Jenkins et al., 2011 portfolio-diet RCT (JAMA; 345 hyperlipidemic participants over 6 months: −13.1% to −13.8% LDL for viscous fiber, nuts, soy/plant protein, and plant sterols versus −3.0% for the low-saturated-fat control). The post names neither study, and the 23% is a trial-population relative effect over years of treatment—not an individual guarantee or a lab-interpretation directive. The dashboard records an attributed claim with verified literature context, not medical advice.

On August 27, Johnson published a self-reported sexual-health “personal best”: 4 hr 2 min of nighttime erections (NTE) at 93% strength, ranked against a personal database of 55,000 measurements, calling NTE “a tier 1 longevity biomarker as critical to systemic health as VO2 max, resting heart rate, HRV, and blood pressure.” He claimed low nighttime-erection scores mean “2x risk of heart attack and stroke in the next 4 years” and listed his protocol: high sleep quality, cardiovascular fitness, a calm nervous system, and daily tadalafil 5 mg (“I take this longevity medication daily”). The direction is documented—erectile dysfunction precedes and predicts cardiovascular events—but the post’s specifics outrun the literature: the Vlachopoulos et al., 2011 JACC meta-analysis (12 cohorts, 36,744 men) pooled RR 1.48 for CVD and 1.35 for stroke, and the Krimpen population cohort found HR 2.6 for MI, stroke, or sudden death only in severely reduced rigidity over roughly six years. The post names no study; its flat “2x in 4 years” is stronger than the meta-analytic averages; consumer NTE scores are not a validated clinical risk tool; and daily tadalafil is a prescription medication requiring clinician oversight. The dashboard records an attributed N=1 biomarker claim with literature context—not a validated risk prediction, a monitoring recommendation, or medical advice. The same batch’s “3x better at predicting the right cancer treatment when biology is tracked longitudinally” post and a truncated retweet were reviewed and kept as chronology-only claims without identifiable sources.

On August 28–29, the NTE arc moved from personal data to population framing. Johnson posted age-binned nightly-duration tables—190 minutes at age 20, 103 at 50, 81 at 60, and 50 at 75+—repeating the ED-precedes-cardiovascular-disease framing and the 2x-in-4-years risk figure. The age decline is genuinely well documented (Karacan et al., 1975 normative NPT series of 125 males aged 3–79; Schiavi et al., 1988 showing progressive decline independent of sleep changes; Horita & Kumamoto, 1989: 189.6 minutes at age 20 declining to roughly 62 minutes at age 70, which puts his age-20 anchor almost exactly on published values), but the post names no study and its intermediate bins match no single published cohort—older-age values differ between series, and consumer NTE scores remain unvalidated as a clinical risk tool. The dashboard records an attributed normative-data claim with literature context, not a risk prediction or medical advice. The same window’s dunk-training strength PR (365 lbs × 2 at age 49) and a Baseten longevity-event recap (3,500 applicants for 150 spots) were reviewed and kept as chronology-only posts that do not materially change the public knowledge model.

On August 30, the feed produced two substantive updates. Johnson declared Kate Tolo’s current menstrual cycle “the most measured menstrual cycle in history,” posting running totals after “waiting for 34 days”: 408 minutes of Kernel brain data, roughly 10,000 blood-glucose readings, 48,960 core-temperature readings from an ingestible pill, 136 body photographs, and a stated 14 million total data points, across a roughly thirty-item measurement inventory spanning cortisol, DNA methylation, oral/stool/vaginal microbiomes, urine hormone metabolites, cervical mucus, sleep, wearables, resting metabolic rate, reaction time, and skin biological age—calling Tolo “the world’s most measured woman.” The totals match the scale of the 100-day, 14-million-datapoint baseline announced in July, so this reads as a mid-program tally of self-reported counts with no dataset, assay methods, results, or clinical interpretation; the dashboard records an attributed N=1 program readout, not completed female-health evidence, a representative protocol, or medical advice. The same day, Johnson published regional percentiles from his own Kernel brain measurements—amygdala 95th, putamen 99th, caudate 97th, globus pallidus 93rd, frontal gray matter 78th and “climbing” (up 1.35% over two years)—and mapped each region onto his personality, citing twin-study heritability of roughly 0.75–0.89 for the subcortical regions while naming no study. The plasticity literature he gestured at is real: Draganski et al., 2004 (Nature) found a transient, selective gray-matter expansion in visual-motion cortex from three months of learning to juggle, which receded once practice stopped, and Colcombe et al., 2006 (J Gerontol A) found frontal gray/white-matter gains from six months of aerobic exercise in sedentary adults aged 60–79. Neither validates region-by-region self-interpretation, the normative cohort behind the percentiles is undisclosed, and Johnson himself closes with “speculative for my n of 1 context.” The dashboard records an attributed self-report with literature context—not a validated brain-health metric, evidence that his protocol grew his frontal cortex, or medical advice. The same batch’s son-photo post, sleep-status aphorism, and Rutger Bregman technology-alarm quote-post were reviewed and kept as chronology-only posts that do not materially change the public knowledge model.

On September 1–2, the feed produced three window-defining updates. Johnson declared that “in many ways, I am 18”—an alien would struggle to distinguish him from his son—and listed fourteen systems he says are indistinguishable from an 18-year-old (sleep quality, erection function, fertility, resting heart rate, vascular and cardiovascular health, blood pressure, metabolic health, blood glucose control, bone mineral density, muscle, fat, “undetectable” inflammation, and, jokingly, shitposting) while conceding two measures remain age-typical: hearing and somatic mutations. He framed the result as “the first rep,” said it took five years, and told readers in their 30s–60s that “the answer is yes” because “the most powerful things are free, and gated only by choice.” The post publishes no dataset, assay methods, reference cohort, or comparison standard for any listed system; the dashboard records an attributed N=1 outcome claim, not evidence of system-by-system youthful equivalence, a replication promise, or medical advice. Separately, a cafe’s caffeinated-instead-of-decaf mistake became a two-part chronology: Johnson first reported wrecked sleep and cancelled morning dunk training citing that “acute sleep disruption can increase injury risk by 70-130%,” then returned with a sound meter and published the investigation—~75 dBA cafe background against his replicated 72 dBA order volume (a −3 dB signal-to-noise ratio where the two orders sound nearly identical), a photographed order screen with adjacent identical “brewed” buttons inviting a capture error, a cited ~1-in-8 cafe order error rate, and an estimated ~55% chance the barista recognized him. The forensic habit is a genuine algorithmic-health signal, but the injury figure names no study and the nearest literature does not match it: chronic insufficient sleep in adolescent athletes raises injury risk 1.7× multivariate (Milewski et al., 2014, J Pediatr Orthop; 112 athletes, <8 h/night; RR 2.1 univariate) and up to 2.25× when training load rises while sleep falls (von Rosen et al., 2017, Scand J Med Sci Sports; 496 athletes)—season-long associations in young athletes, not acute single-night disruption in a 49-year-old. The dashboard records an attributed event narrative and self-measurement example with literature context, not a validated acute-injury statistic, sleep guidance, or medical advice. Earlier, on August 31, Johnson live-logged the start of Kate Tolo’s period as an operational event: bleeding began 10:34 am, the cells “start dying immediately,” a lab must process the sample within 24 hours, and an “entire global team” activated cup, tubes, ice, packing, and overnight courier inside a roughly six-hour window to collect 7 mL of menstrual blood, with a missed window meaning a 35-day delay. That post executes the July 31 menstrual-blood-as-uterine-sample proposal and shows the program’s operational intensity, but reports only timing and volume—no assay, analysis, or validation—so it stays an attributed N=1 program-operations update, not a validated diagnostic workflow or medical advice. The same window’s dunk-training vertical-jump estimates (28” vertical, 12.3 ft/s takeoff, front squat 245 lbs PR toward a 10-foot-rim dunk) and the “I’m best a foil for others” aphorism were reviewed and kept as chronology-only posts consistent with prior dunk-post skip decisions.

On September 4, the measurement thesis moved from self-report to product. Johnson announced an AI model built on sleep data that “accurately predicts your age,” developed with Eight Sleep CEO Matteo Franceschetti and available on their platforms. The post is unusually checkable because a preprint exists, and its headline numbers match: BCG-FM (Kjaer et al., arXiv:2606.07692) pretrained with contrastive learning on 2.04 million hours of nightly bed-sensor ballistocardiography from 136,575 participants, reporting biological age within 3.26 years MAE (the lowest reported for any ambient, contactless modality), 92.5% Rank-1 identity retrieval from one night’s signal, and disease AUROCs of 0.852 for diabetes, 0.822 for heart failure on external cohorts, 0.810 for hypertension, 0.792 for sleep apnea, 0.751 for snoring, and 0.734 for general heart conditions, with log-linear batch-size scaling (R²=0.982). The boundaries stay visible: the model backs a vendor membership feature (“Biological Age,” co-developed with Johnson’s Immortals), the internal disease labels are self-reported, the external cohorts are small, the preprint is not peer-reviewed, and the post’s “diabetes better than Apple’s model” has no corresponding comparison in the preprint—its Apple-Watch PpgAge benchmark is age accuracy (2.43-year MAE on a healthy cohort), not disease detection. Johnson’s own post concedes the limitations and calls it “a research milestone, not a diagnostic device,” framed as his “Autonomous Health” thesis in practice. The dashboard records an attributed product-launch and research claim with verified preprint context—not a validated diagnostic, a purchasing signal, or medical advice. The same batch’s dunk-training strength PR (385 lbs, +20 from last week, with his self-computed 97%-strength / 55%-power framing), 4:30 am wake-time post, and between-sets jump video were reviewed and kept as chronology-only posts consistent with prior dunk-post skip decisions.

Reading stance

Use Johnson as a high-signal case study in biomarker driven longevity protocols, but keep claims separated into: (1) independently verifiable biography/business facts, (2) Johnson/Blueprint primary-source health claims, and (3) third-party scientific/medical interpretation. His transparency and measurement density are useful; the N=1 design, simultaneous intervention changes, commercial incentives, and reliance on surrogate biomarkers limit generalizability.